Eisai Issues Statement after 3rd Death Potentially Tied to Lecanemab Reported

Eisai on December 23 issued a statement stressing the company’s respect for safety following a media report on a third patient death potentially linked to its Alzheimer’s drug lecanemab in a PIII extension study. The Japanese company, which is leading...read more